Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Mariagrazia Michieli, MD
- Phone Number: 0434 659 020
- Email: mmichieli@cro.it
Study Locations
-
-
Pordenone
-
Aviano, Pordenone, Italy, 33081
- Recruiting
- Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
-
Contact:
- Mariagrazia Michieli, MD
- Phone Number: 0434 659 020
- Email: mmichieli@cro.it
-
Principal Investigator:
- Mariagrazie Michieli, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age≥ 18 years;
- Diagnosis of multiple myeloma;
- Clinical indication and eligibility for vertebroplasty procedure;
- Performance Status (ECOG) 0-2;
- Life expectancy greater than three months;
- Low-resolution full skeletal CT scan at disease onset and/or at follow-up;
- Spine pain with stiffness and functional impediment pre vertebroplasty;
- Able to express appropriate consent for participation in the study (e.g. Able to understand Italian, patient with intact cognitive abilities)
Exclusion Criteria:
- presence of spinal cord compressions;
- unstable spinal injuries, requiring an orthopaedic back brace;
- risk of spinal cord injury;
- body mass index BMI>28 kg/m2.
- absence of signed informed consent form
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
MM patient candidate to vertebroplasty
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in mean of kinematic data for walking before and after vertebroplasty
Time Frame: 2 months
|
Difference in mean of kinematic data for walking before and after vertebroplasty
|
2 months
|
|
difference in mean of movement range for affected joints before and after vertebroplasty
Time Frame: 2 months
|
difference in mean of movement range for affected joints before and after vertebroplasty
|
2 months
|
|
Difference in mean of energy expenditure before and after vertebroplasty
Time Frame: 2 months
|
Difference in mean of energy expenditure before and after vertebroplasty
|
2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To explore the impact of vertebroplasty on thermal parameters
Time Frame: 2 months
|
Central and superficial temperature will be measured before and after vertebroplasty.
Difference will be reported as intrapatient mean difference
|
2 months
|
|
To explore the impact of vertebroplasty on metabolic parameters
Time Frame: 2 months
|
Carbon dioxide production after 30 minutes of walking will be measured before and after vertebroplasty and intrapatient mean difference will be reported.
|
2 months
|
|
To explore the impact of vertebroplasty on metabolic parameters
Time Frame: 2 months
|
Cardiac frequency after 30 minutes of walking will be measured before and after vertebroplasty and intrapatient mean difference will be reported.
|
2 months
|
|
To explore the impact of vertebroplasty on metabolic parameters
Time Frame: 2 months
|
Oxygen consumption after 30 minutes of walking will be measured before and after vertebroplasty and intrapatient mean difference will be reported.
|
2 months
|
|
To explore the impact of vertebroplasty on pain
Time Frame: 2 months
|
Perceived pain will be measured using the Brief Pain Inventory scale (BPI) before and after vertebroplasty.
Difference will be reported as intrapatient mean difference.
BPI values range between 0 and 10, with higher scores meaning worst pain
|
2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mariagrazia Michieli, MD, Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
Other Study ID Numbers
- CRO-2020-35
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.